Seneca Biopharma Inc fka SNCA

[jugs]

April's very recent addition to her ALS blog indicated that her perceived response during Phase 11 of the Emory U. trial has not impressed would-be investors. This is disappointing as she has certainly been of huge help to those of us outside of the clinical trial. I'm not thinking about my share position one way or the other as that doesn't spell my reasons for being long.

That said, I think we will have to wait for Dr. Feldman's official report which I believe will be forthcoming no sooner than July. I'm counting on nothing but it would be a godsend, were it to be the ultimate convincer that we're on the right track to be of help to some truly beleaguered victims of illness.

For those seeing profitable trades, there's opportunity here: Last week I added 500 shares on a dip to $3.04. At this moment I'm seeing $3.47. Should there be a similar dip in the weeks ahead, it might be smart to add a thousand or two as it appears to be a relatively safe move PRIOR to the release of pertinent info relating to the ongoing trial.

My opinions only in the above.